PH12017501699B1 - Fused bicyclic heteroaryl derivatives having activity as phd inhibitors - Google Patents

Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Info

Publication number
PH12017501699B1
PH12017501699B1 PH1/2017/501699A PH12017501699A PH12017501699B1 PH 12017501699 B1 PH12017501699 B1 PH 12017501699B1 PH 12017501699 A PH12017501699 A PH 12017501699A PH 12017501699 B1 PH12017501699 B1 PH 12017501699B1
Authority
PH
Philippines
Prior art keywords
activity
bicyclic heteroaryl
fused bicyclic
heteroaryl derivatives
phd inhibitors
Prior art date
Application number
PH1/2017/501699A
Other languages
English (en)
Other versions
PH12017501699A1 (en
Inventor
Saleh; Ahmed
Gregory Barker
Hannah Canning
Richard Davenport
David Harrison
Kerry Jenkins
Natasha Kinsella
David Livermore
Susanne Wright
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PH12017501699A1 publication Critical patent/PH12017501699A1/en
Publication of PH12017501699B1 publication Critical patent/PH12017501699B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
PH1/2017/501699A 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors PH12017501699B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds
PCT/JP2016/059782 WO2016148306A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Publications (2)

Publication Number Publication Date
PH12017501699A1 PH12017501699A1 (en) 2018-03-12
PH12017501699B1 true PH12017501699B1 (en) 2023-06-30

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2017/501699A PH12017501699B1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Country Status (31)

Country Link
US (1) US10287286B2 (OSRAM)
EP (1) EP3271357B1 (OSRAM)
JP (1) JP6726681B2 (OSRAM)
KR (1) KR102609431B1 (OSRAM)
CN (1) CN107531698B (OSRAM)
AU (1) AU2016234209B2 (OSRAM)
BR (1) BR112017019653B1 (OSRAM)
CA (1) CA2979024C (OSRAM)
CL (1) CL2017002354A1 (OSRAM)
CO (1) CO2017009353A2 (OSRAM)
CR (1) CR20170468A (OSRAM)
DK (1) DK3271357T3 (OSRAM)
DO (1) DOP2017000209A (OSRAM)
EA (1) EA035739B1 (OSRAM)
EC (1) ECSP17069696A (OSRAM)
ES (1) ES2774052T3 (OSRAM)
GB (1) GB201504565D0 (OSRAM)
GE (1) GEP20207095B (OSRAM)
HU (1) HUE047918T2 (OSRAM)
IL (1) IL254277B (OSRAM)
MX (1) MX2017011902A (OSRAM)
MY (1) MY194873A (OSRAM)
NZ (1) NZ735631A (OSRAM)
PE (1) PE20180656A1 (OSRAM)
PH (1) PH12017501699B1 (OSRAM)
PT (1) PT3271357T (OSRAM)
SG (1) SG11201707280VA (OSRAM)
TN (1) TN2017000384A1 (OSRAM)
UA (1) UA123668C2 (OSRAM)
WO (1) WO2016148306A1 (OSRAM)
ZA (1) ZA201706612B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017222417B2 (en) 2016-02-24 2020-07-09 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK-inhibitors
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
KR102830577B1 (ko) * 2018-09-13 2025-07-08 깃세이 야쿠힌 고교 가부시키가이샤 이미다조피리디논 화합물
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
CN115413277B (zh) * 2020-04-20 2023-08-01 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
AR123848A1 (es) * 2020-10-20 2023-01-18 Amgen Inc Compuestos espiro heterocíclicos y métodos de uso
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
IL312220A (en) 2021-10-28 2024-06-01 Insilico Medicine Ip Ltd Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的phd1阻害剤化合物、組成物、及び使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
SK18412002A3 (sk) 2000-06-30 2003-06-03 Wyeth Použitie substituovaných triazolopyrimidínových derivátov a farmaceutický prostriedok s ich obsahom
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
TWI485150B (zh) * 2009-07-17 2015-05-21 Japan Tobacco Inc 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用
JP2011168582A (ja) 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
JPWO2014030716A1 (ja) * 2012-08-23 2016-08-08 田辺三菱製薬株式会社 ピラゾロピリミジン化合物

Also Published As

Publication number Publication date
UA123668C2 (uk) 2021-05-12
US20180072714A1 (en) 2018-03-15
PH12017501699A1 (en) 2018-03-12
MY194873A (en) 2022-12-21
JP2018512408A (ja) 2018-05-17
JP6726681B2 (ja) 2020-07-22
GEP20207095B (en) 2020-04-10
HK1249512A1 (en) 2018-11-02
NZ735631A (en) 2023-07-28
ES2774052T3 (es) 2020-07-16
CO2017009353A2 (es) 2017-11-30
BR112017019653A2 (pt) 2018-05-15
CA2979024A1 (en) 2016-09-22
ZA201706612B (en) 2019-01-30
GB201504565D0 (en) 2015-05-06
IL254277A0 (en) 2017-10-31
DK3271357T3 (da) 2020-02-17
EA201792057A1 (ru) 2018-04-30
KR20170129874A (ko) 2017-11-27
HUE047918T2 (hu) 2020-05-28
EP3271357A1 (en) 2018-01-24
BR112017019653B1 (pt) 2023-10-03
CN107531698A (zh) 2018-01-02
TN2017000384A1 (en) 2019-01-16
KR102609431B1 (ko) 2023-12-04
EP3271357B1 (en) 2019-11-27
EA035739B1 (ru) 2020-08-03
AU2016234209B2 (en) 2020-08-27
WO2016148306A1 (en) 2016-09-22
US10287286B2 (en) 2019-05-14
ECSP17069696A (es) 2018-02-28
PT3271357T (pt) 2020-02-21
PE20180656A1 (es) 2018-04-17
CR20170468A (es) 2018-04-27
CL2017002354A1 (es) 2018-05-04
MX2017011902A (es) 2017-12-15
AU2016234209A1 (en) 2017-10-12
SG11201707280VA (en) 2017-10-30
CN107531698B (zh) 2024-08-13
CA2979024C (en) 2024-02-20
DOP2017000209A (es) 2017-10-15
IL254277B (en) 2020-10-29

Similar Documents

Publication Publication Date Title
NZ735631A (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
PH12018501920B1 (en) Bromodomain inhibitors
PH12018502515B1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018500591B1 (en) Heterocyclic compounds and uses thereof
PH12016501440A1 (en) Novel heterocyclic compounds
MY199735A (en) Jak1 selective inhibitors
WO2015200677A3 (en) Prmt5 inhibitors and uses thereof
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
TW201613864A (en) Novel compounds
EA033281B1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists